BioPharm America™ 2017: Morphic Therapeutics finds new approach for reaching targets

#111: PentaMice™: A Unique Approach to Achieve Maximum Plasma Titers for Antibody Discovery WebinarПодробнее

BioFitness Interface 4.0 (Морфическое поле)Подробнее

Посмотреть моложе - Виртуальные процедуры для лица и тела (Морфическое поле)Подробнее

BioPharm America™ 2017: NCI serves as a partner to advance drug developmentПодробнее

Advanced Acne Treatment - (Morphic Field)Подробнее

Mesoblast prepares to launch FDA-approved therapy for Pediatric Steroid-Refractory aGVHDПодробнее

$Mesoblast prepares to launch FDA-approved therapy for Pediatric Steroid-Refractory aGVHD$

Quantum DNA Revitalizer: The Healing Blueprint (Morphic FIeld)Подробнее

BioPharm America 2015 presents Biomarkers and Precision MedicineПодробнее

FOAB - Father of All Boosters - (Morphic Field)Подробнее

Dermata Therapeutics, Inc. (NASDAQ: DRMA)Подробнее

Immatics Therapeutic ApproachПодробнее

The Science of Shaping Your IdentityПодробнее

Nimble Therapeutics greatly accelerates the development of peptide-based therapeuticsПодробнее

Therapeutic Antibody Discovery—GenScriptПодробнее

$8 million awarded to predict genetic disease riskПодробнее

Top Gainer Today in the Stock Market (Morphic Holding Inc) #shortsПодробнее

Exploring target-disease associations with the Open Targets Platform’s new interfaceПодробнее